HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Reticulocytosis and anemia are associated with an increased risk of death and stroke in the newborn cohort of the Cooperative Study of Sickle Cell Disease.

Abstract
Prior analyses of the Cooperative Study of Sickle Cell Disease (CSSCD) newborn cohort identified elevated white blood cell (WBC) count, low baseline hemoglobin and dactylitis between the ages of 1 and 2 years as markers of severe disease. Reticulocytosis was also associated with severe disease. Here, we further analyzed data collected on enrolled CSSCD infants for the predictive value of those markers for stroke and death later in life. Three hundred fifty-four CSSCD subjects were identified who had absolute reticulocyte counts (ARC) measured during infancy (2 to 6 months of age). Infants with higher ARC had significantly increased risk of stroke or death during childhood; lower hemoglobin levels also increased the risk but to a lesser degree than ARC. WBC levels and dactylitis were not predictive of death or stroke. These data suggest that reticulocytosis among asymptomatic infants with sickle cell anemia is associated with an increased risk of death or stroke during childhood.
AuthorsEmily Riehm Meier, Elizabeth C Wright, Jeffery L Miller
JournalAmerican journal of hematology (Am J Hematol) Vol. 89 Issue 9 Pg. 904-6 (Sep 2014) ISSN: 1096-8652 [Electronic] United States
PMID24891147 (Publication Type: Journal Article, Research Support, N.I.H., Extramural, Research Support, N.I.H., Intramural)
Copyright© 2014 Wiley Periodicals, Inc.
Chemical References
  • Hemoglobins
Topics
  • Anemia, Sickle Cell (blood, complications, mortality)
  • Child, Preschool
  • Female
  • Hemoglobins (analysis)
  • Humans
  • Infant
  • Infant, Newborn
  • Kaplan-Meier Estimate
  • Leukocyte Count
  • Male
  • Predictive Value of Tests
  • Reticulocyte Count
  • Reticulocytes (cytology)
  • Reticulocytosis
  • Risk
  • Stroke (blood, etiology, mortality)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: